This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William R. Shapiro, MD

Arch Neurol. 1975;32(10):653-656.

Abstract
• A new antidepressant drug, clomipramine hydrochloride, closely related to imipramine hydrochloride, was used to treat four patients suffering from cataplexy, sleep paralysis, and hypnagogic hallucinations. Attacks of cataplexy were associated with rapid-eye-movement (REM) electroencephalographic patterns. Clomipramine, in doses of 25 to 75 mg/ day, completely stopped all attacks of cataplexy, sleep paralysis, and hypnagogic hallucinations within 48 hours of initial therapy. The patients have been free of symptoms for periods of 10 to 21 months. Side effects included impotence in the male patients, but no hematologic, cardiovascular, hepatic, or renal toxic effects were observed. Available evidence suggests that such drugs inhibit those brain stem systems that control the toxic components of REM sleep.

Author Affiliations
From the Neuropsychiatric Service, Memorial Sloan-Kettering Cancer Center; and the Department of Neurology, Cornell University Medical College, New York.

Footnotes
Accepted for publication Oct 23, 1974.

Read before the 99th annual meeting of the American Neurological Association, Boston, June 11, 1974.

Reprint requests to Neuropsychiatric Service, Memorial Sloan-Kettering Cancer Center, 444 E 68th St, New York, NY 10021 (Dr. Shapiro).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diagnosing Narcolepsy Through the Simultaneous Clinical and Electrophysiologic Analysis of Cataplexy
Dyken et al.
Arch Neurol 1996;53:456-460.
ABSTRACT